| Asthmatic pulmonary eosinophilia
Cinqair vs Fasenra
Side-by-side clinical, coverage, and cost comparison for asthmatic pulmonary eosinophilia.Deep comparison between: Cinqair vs Fasenra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFasenra has a higher rate of injection site reactions vs Cinqair based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fasenra but not Cinqair, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cinqair
Fasenra
At A Glance
IV infusion
Every 4 weeks
IL-5 antagonist
SC injection
Every 4-8 weeks
IL-5 receptor alpha antagonist
Indications
- Asthmatic pulmonary eosinophilia
- Asthmatic pulmonary eosinophilia
- Eosinophilic granulomatosis with polyangiitis
Dosing
Asthmatic pulmonary eosinophilia 3 mg/kg once every 4 weeks by intravenous infusion over 20-50 minutes.
Asthmatic pulmonary eosinophilia Adults and adolescents >=12 years: 30 mg SC every 4 weeks for first 3 doses, then every 8 weeks; pediatric 6-11 years weighing <35 kg: 10 mg SC every 4 weeks for first 3 doses, then every 8 weeks; pediatric 6-11 years weighing >=35 kg: 30 mg SC every 4 weeks for first 3 doses, then every 8 weeks.
Eosinophilic granulomatosis with polyangiitis 30 mg SC once every 4 weeks.
Contraindications
- Known hypersensitivity to reslizumab or any of its excipients
- Known hypersensitivity to benralizumab or any of its excipients
Adverse Reactions
Most common (>=2%) Oropharyngeal pain
Serious Anaphylaxis, malignancy
Musculoskeletal CPK elevations, myalgia, musculoskeletal chest pain, neck pain, muscle spasms, extremity pain, muscle fatigue, musculoskeletal pain
Most common (>=3%) Headache, pyrexia, pharyngitis, hypersensitivity reactions (urticaria, rash)
Postmarketing Hypersensitivity reactions, including anaphylaxis
Pharmacology
Reslizumab is an IL-5 antagonist (IgG4, kappa) that binds IL-5 with high affinity (Kd 81 pM), blocking its binding to the IL-5 receptor alpha chain on eosinophils and thereby inhibiting eosinophil growth, differentiation, recruitment, activation, and survival.
IL-5 receptor alpha antagonist; benralizumab is a humanized afucosylated IgG1 monoclonal antibody that binds the IL-5 receptor alpha subunit on eosinophils and basophils, inducing apoptosis via antibody-dependent cell-mediated cytotoxicity (ADCC) through NK cell Fc-gamma-RIII engagement.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cinqair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Fasenra
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Cinqair
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Fasenra
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (2/8) · Qty limit (0/8)
Humana
Cinqair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Fasenra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CinqairView full Cinqair profile
FasenraView full Fasenra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.